Osteogenesis Imperfecta (OI) or brittle bone disease is the most common primary osteodysplasia of the skeleton. In 2006, our group and collaborators defined the mechanistic basis of a unique post-translational modification of fibrillar collagens, i.e., 3-prolyl-hydroxylation, to involve a trimeric complex composed of Cartilage Associated Protein (CRTAP), Prolyl hydroxylase 1 (P3H1 encoded by LEPRE1), and Cyclophiliin B (CYPB) also known as peptidy-prolyl isomerase B (encoded by PPIB). We and others have since demonstrated that mutations in these genes account for the majority of remaining cases that constitute a recessively inherited class of OI. Biochemically, we know that mutations in these genes can be associated with a panoply of biochemical and cell biological changes: 1) intracellular posttranslational overmodification of collagen, 2) dilatation and disorganization of cellular organelles including the rough endoplasmic reticulum (rER), 3) alteration in secretion and fibrillogenesis, 4) dysregulation of extracellular collagen processing including propeptide cleavage and fibril crosslinking, and 5) altered rates of osteoid deposition and matrix mineralization. Still, we do not know how these alterations contribute to the clinical picture of OI. Importantly, the fact that we cannot easily distinguish the clinical features caused by diverse genetic mutations and biochemical alterations supports the hypothesis that there are underiying common mechanisms of cellular and tissue dysfunction that lead to brittle bone. In this project, we propose to dissect the two biochemical activities of the 3-prolyl hydroxylase complex, i.e., 3-prolyl-hydroxylation of fibrillar collagens vs. chaperone function of collagen, to determine whether alterations in matrix cell signaling may be a common mechanism in the pathogenesis of recessive OI, and to identify novel genetic causes of OI, specifically types V and VI.
By studying how mutations that affect a group of genes that modify collagen function translate into bone fragility in osteogenesis imperfecta, we hope to identify novel therapies and improved diagnostic tools.
|Lietman, Caressa D; Marom, Ronit; Munivez, Elda et al. (2015) A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res 30:489-98|
|Homan, Erica P; Lietman, Caressa; Grafe, Ingo et al. (2014) Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues. PLoS Genet 10:e1004121|
|Hudson, David M; Werther, Rachel; Weis, MaryAnn et al. (2014) Evolutionary origins of C-terminal (GPP)n 3-hydroxyproline formation in vertebrate tendon collagen. PLoS One 9:e93467|
|Joeng, Kyu Sang; Lee, Yi-Chien; Jiang, Ming-Ming et al. (2014) The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. Hum Mol Genet 23:4035-42|
|Murali, Chaya; Lu, James T; Jain, Mahim et al. (2014) Diagnosis of ALG12-CDG by exome sequencing in a case of severe skeletal dysplasia. Mol Genet Metab Rep 1:213-219|
|Martin, Brett M; Ivanova, Margarita H; Sarukhanov, Anna et al. (2014) Prenatal and postnatal findings in serpentine fibula polycystic kidney syndrome and a review of the NOTCH2 spectrum disorders. Am J Med Genet A 164A:2490-5|
|Rajagopal, Abbhirami; Braslavsky, Débora; Lu, James T et al. (2014) Exome sequencing identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis. J Clin Endocrinol Metab 99:E2451-6|
|Chen, Shan; Lee, Brendan H; Bae, Yangjin (2014) Notch signaling in skeletal stem cells. Calcif Tissue Int 94:68-77|
|Tao, Jianning; Jiang, Ming-Ming; Jiang, Lichun et al. (2014) Notch activation as a driver of osteogenic sarcoma. Cancer Cell 26:390-401|
|Posey, Jennifer E; Burrage, Lindsay C; Miller, Marcus J et al. (2014) Lysinuric Protein Intolerance Presenting with Multiple Fractures. Mol Genet Metab Rep 1:176-183|
Showing the most recent 10 out of 24 publications